AstraZeneca Pharma India Ltd Stock Price Today (NSE: ASTRAZEN)
Fundamental Score
AstraZeneca Pharma India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
AstraZeneca Pharma India Ltd share price today is ₹8512.50, up +0.11% on NSE/BSE as of 17 June 2026. AstraZeneca Pharma India Ltd (ASTRAZEN) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹22.61K (Cr). The 52-week high for ASTRAZEN share price is ₹10392.50 and the 52-week low is ₹7551.50. At a P/E ratio of 97.79x, ASTRAZEN is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 23.63% and a debt-to-equity ratio of 0.04.
AstraZeneca Pharma India Ltd Share Price Chart — NSE/BSE Historical Performance
AstraZeneca Pharma India Ltd share price chart: 0.88% return over the past month. 52-week high ₹10392.50, 52-week low ₹7551.50.
AstraZeneca Pharma India Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹8790.00 | ₹8790.00 | ₹8650.00 | ₹8710.00 | 4.05K (Cr) | |
| ₹8640.00 | ₹8800.00 | ₹8555.50 | ₹8729.00 | 9.22K (Cr) | |
| ₹8600.00 | ₹8820.00 | ₹8431.50 | ₹8631.50 | 29.55K (Cr) | |
| ₹8826.00 | ₹8826.00 | ₹8357.00 | ₹8648.00 | 80.17K (Cr) | |
| ₹8746.50 | ₹9150.00 | ₹8719.50 | ₹8962.50 | 26.45K (Cr) | |
| ₹8609.00 | ₹8895.00 | ₹8554.00 | ₹8800.00 | 9.29K (Cr) | |
| ₹8589.50 | ₹8661.50 | ₹8562.00 | ₹8587.50 | 1.70K (Cr) | |
| ₹8708.00 | ₹8708.00 | ₹8574.50 | ₹8589.50 | 4.40K (Cr) | |
| ₹8700.00 | ₹8815.00 | ₹8580.00 | ₹8609.50 | 6.79K (Cr) | |
| ₹8524.50 | ₹8736.00 | ₹8489.50 | ₹8695.50 | 5.83K (Cr) |
AstraZeneca Pharma India Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹8640.00 | ₹8800.00 | ₹8555.50 | ₹8710.00 | +0.81% | |
| ₹8300.00 | ₹9150.00 | ₹8010.00 | ₹8631.50 | +3.99% | |
| ₹7970.00 | ₹8900.00 | ₹7551.50 | ₹8213.00 | +3.05% | |
| ₹8352.00 | ₹8859.50 | ₹7677.00 | ₹7765.50 | -7.02% | |
| ₹8574.00 | ₹9220.00 | ₹8430.50 | ₹8849.00 | +3.21% | |
| ₹9000.00 | ₹9064.00 | ₹8020.00 | ₹8550.00 | -5.00% | |
| ₹9040.00 | ₹9264.00 | ₹8617.50 | ₹9029.00 | -0.12% | |
| ₹9555.00 | ₹9849.50 | ₹8828.50 | ₹9024.00 | -5.56% | |
| ₹9100.00 | ₹9599.00 | ₹9000.00 | ₹9555.00 | +5.00% | |
| ₹8460.00 | ₹9242.00 | ₹8403.50 | ₹9105.50 | +7.63% | |
| ₹9175.00 | ₹9221.00 | ₹7955.00 | ₹8460.50 | -7.79% | |
| ₹8910.00 | ₹9650.50 | ₹8822.50 | ₹9186.00 | +3.10% |
AI Research Briefing
Powered by Gemini · 2026-04-09
AstraZeneca Pharma India is priced for unrealistic perfection; growth is already slowing.
WHAT'S HAPPENING NOW (last 2-4 weeks)
AstraZeneca Pharma India shareholders approved in related party transactions with AstraZeneca UK and AstraZeneca AB, Sweden. Approvals came via postal ballot. Mr. Jesús Diaz-Ropero Esteso resigned as Non-Executive Director. Trading window closed March 16 for FY26 results. Stock hit an intraday low of on March 27, down 7.02%.
CORE STORY (THE REAL GAME)
Not a generics play. AstraZeneca Pharma India is a bet on innovative therapies gaining traction in the Indian market, riding on the global parent's R&D and portfolio. It's about premium pricing and market share in specialized segments like oncology and rare diseases, not volume-driven generics.
- Q3 growth of 39%
- 8 new regulatory approvals
- Shareholder approval of related party transactions
- Positive drug trial outcomes
- Faster regulatory approvals
- New product launches in India
- High P/E ratio
- Related party transactions
- Dependence on parent company
FII decreased stake by 0.29%, DII increased stake by 0.71% [cite:]
India Pharma industry projected to reach $130 Billion by 2030
Yes - Free Cash Flow 5Y: ₹329.01 Cr [cite:]
Growth in innovative therapies will drive revenue. Monitor regulatory approvals and related party transactions.
Primary Thesis Risk
Overvaluation leaves no room for error.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
AstraZeneca Pharma India Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
AstraZeneca Pharma India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ASTRAZEN across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (23.63%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (33.40%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Robust Profit Growth (51.26%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (37.03%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (15.59% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (19.45% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (19.45% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (131.37x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹329.01 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 97.79x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Institutional Interest (FII+DII: 8.00%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
AstraZeneca Pharma India Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare AstraZeneca Pharma India Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
AstraZeneca Pharma India LtdAstraZeneca Pha...Selected✓ ASTRAZEN • 506820 | 65.5/100 | ₹8512.50₹8513 | ₹22605.38₹22605.38 | 97.79Average 97.8 Average | 23.63%Excellent 23.63% Excellent | 33.40%Excellent 33.40% Excellent | 0.04Excellent 0.0 Excellent | 19.45%Excellent 19.45% Excellent | 15.59%Excellent 15.59% Excellent | 0.35% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
AstraZeneca Pharma India Ltd PE Ratio History
Historical price-to-earnings ratio for ASTRAZEN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹46.30 | ₹9029.00 | 195x |
| FY 2024 | ₹64.60 | ₹7305.15 | 113.1x |
| FY 2023 | ₹39.70 | ₹5526.60 | 139.2x |
| FY 2022 | ₹24.60 | ₹3297.15 | 134x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
AstraZeneca Pharma India Ltd Dividend History
Annual cash dividends paid by ASTRAZEN — dividend yield 0.35%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹60.00 Cr |
| FY 2024 | ₹40.00 Cr |
| FY 2023 | ₹20.00 Cr |
| FY 2022 | ₹5.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
AstraZeneca Pharma India Ltd Quarterly Performance
Latest quarterly metrics for ASTRAZEN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
37.03%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
51.26%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.59%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
19.45%
Compounded annual net profit growth over 5 years
AstraZeneca Pharma India Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ASTRAZEN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
AstraZeneca Pharma India Ltd Financial Statements
Annual income statement, balance sheet and cash flow for AstraZeneca Pharma India Ltd (ASTRAZEN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for AstraZeneca Pharma India Ltd
About ASTRAZEN (AstraZeneca Pharma India Ltd)
AstraZeneca Pharma India Ltd is a pivotal player in the Indian pharmaceutical landscape, deeply committed to enhancing healthcare outcomes through innovative and accessible medicin...es. The company operates as a crucial subsidiary within the global AstraZeneca network, leveraging its parent company's extensive research and development capabilities to bring cutting-edge therapies to the Indian market. It meticulously navigates the complexities of the Indian healthcare system, striving to address unmet medical needs and improve the lives of patients across a spectrum of therapeutic areas. AstraZeneca India’s unwavering dedication to quality, safety, and efficacy underscores its position as a trusted provider of pharmaceutical solutions within the country. The company adheres to rigorous ethical standards in all its operations, fostering a culture of integrity and accountability throughout the organization. AstraZeneca Pharma India focuses on delivering a broad portfolio of pharmaceutical products that cater to prevalent health challenges in India. The company actively provides treatments for a range of conditions, including respiratory ailments, oncological diseases, and cardiovascular disorders. Their commitment extends to addressing metabolic and immunological conditions, demonstrating a comprehensive approach to patient care. Beyond established therapies, AstraZeneca India remains at the forefront of innovation, continuously seeking opportunities to introduce novel medicines and treatment approaches to the Indian market. This proactive stance reflects its commitment to driving advancements in healthcare and improving patient outcomes through pioneering pharmaceutical solutions. The company’s product pipeline is strategically aligned with the evolving healthcare needs of the Indian population. AstraZeneca Pharma India Ltd contributes significantly to the nation's pharmaceutical industry, fostering economic growth and scientific advancement. The company invests in local manufacturing capabilities, creating employment opportunities and supporting the development of a skilled workforce. Furthermore, AstraZeneca actively engages with healthcare professionals, patient advocacy groups, and regulatory bodies to foster collaborative partnerships and improve access to healthcare. These collaborative efforts are aimed at fostering a conducive environment for pharmaceutical innovation and ensuring that patients receive the best possible care. AstraZeneca India’s long-term vision is centered around becoming a leading healthcare partner in India, recognized for its commitment to innovation, accessibility, and patient-centricity, solidifying its position as a key driver of positive change in the Indian healthcare landscape.
Company Details
Key Leadership
Corporate Events
ASTRAZEN Share Price: Frequently Asked Questions
What is the current share price of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd (ASTRAZEN) trades at ₹8512.50 on NSE and BSE. Market cap ₹22.61K (Cr). Educational data only.
What is the P/E ratio of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has a P/E of 97.79x vs industry average 31.77x.
What is the Bull Run score for AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has a Bull Run score of 65.5/100 based on 25+ financial parameters.
Does AstraZeneca Pharma India Ltd pay dividends?
AstraZeneca Pharma India Ltd has a dividend yield of 0.35%. Past dividends don't guarantee future payments.
What is the ROE of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has ROE of 23.63%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has debt-to-equity of 0.04.
Is AstraZeneca Pharma India Ltd a good investment?
Bull Run gives AstraZeneca Pharma India Ltd a score of 65.5/100. This is not investment advice — consult a SEBI-registered advisor.